Last Updated on July 21, 2024 by The Health Master
Insulin
In a move impacting the diabetes treatment landscape, the US Food and Drug Administration (USFDA) has requested additional information from Novo Nordisk concerning its once-weekly basal insulin icodec.
This news, announced by the Danish drugmaker, delays potential wider availability of the treatment in the United States.
USFDA Seeks Clarification
The USFDA issued a “complete response letter” to Novo Nordisk, outlining its need for further data on two key areas:
- Manufacturing Process: The regulatory body requires more details regarding the production of icodec to ensure it meets stringent quality and safety standards.
- Type 1 Diabetes Indication: Concerns were raised about the use of icodec in patients with Type 1 diabetes, specifically regarding the potential for hypoglycemia (low blood sugar) events.
Next Steps
Novo Nordisk acknowledged the USFDA’s requests and stated they would not be able to address them entirely within 2024.
The company remains committed to collaborating with the USFDA to determine the necessary steps for approval and bring icodec to patients in the US.
Background
Icodec, if approved, would represent a significant advancement in diabetes management.
By offering a once-weekly injection compared to the current standard of daily or multiple daily injections, icodec has the potential to improve treatment adherence and quality of life for patients.
However, the USFDA’s decision reflects some of the concerns raised during the application review process.
An external panel previously expressed reservations regarding the use of icodec in Type 1 diabetes due to potential blood sugar fluctuations.
Global Availability of icodec
While the US approval process faces a hurdle, it’s important to note that icodec has received approval under the brand name Awiqli in other regions, including Europe, Canada, Japan, and Australia.
This suggests that Novo Nordisk remains confident in the drug’s efficacy and safety profile.
Looking Ahead
The delay in icodec’s US approval is a setback for both Novo Nordisk and patients seeking a more convenient insulin treatment option.
It also highlights the USFDA’s rigorous approach to ensuring medication safety and efficacy.
While the timeline for US availability remains uncertain, Novo Nordisk’s commitment to working with the USFDA offers hope for a future approval.
In the meantime, patients with diabetes should continue to follow their current treatment plans as directed by their healthcare providers.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA declines to approve this migraine drug
USFDA declines to approve Nasal Spray for allergic reactions
USFDA declines to approve this Parkinson’s drug
USFDA declines to approve this Hormone Disorder therapy
USFDA declines to approve this Lung Cancer drug
USFDA declines to approve expanded use of this Antipsychotic drug
Excipients: Need to enforce stringent Regulatory Standards for quality
Indian Regulators Cracks Down with Mandatory Barcodes on Top Brands
USFDA approval granted for generic Bromfenac Ophthalmic Solution
NPPA Seeks Clarity on Regulatory Requirements for this Inhaler Device
Inspections to be started for compliance of Revised Schedule M: Tamil Nadu
Govt issues Zika virus advisory: Urgent Action Needed
Budget 2024: Indian Pharma Sector seek incentives for innovation
CDSCO Panel approval granted for Clinical Trial of this Anti Cancer Drug
USFDA approval granted for this BP lowering drug
IPC flags side effects of heart, Glaucoma medicines
High Court: Expedite framing policy for online sale of drugs
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
